RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment
of Mr. Thomas R. Staab, II as BioCryst's new Chief Financial Officer,
effective July 1, 2011, and that Mr. Stuart R. Grant, BioCryst's current
CFO, has agreed to extend his employment with the Company an additional
month to June 30, 2011.
"On behalf of BioCryst's employees and Board of Directors, I wish to
thank Stuart Grant for his four years of dedicated leadership,
unwavering financial discipline and his commitment to a smooth
transition of the financial reins of the company," said Jon
P. Stonehouse, President and Chief Executive Officer, BioCryst
Pharmaceuticals. "Tom Staab brings nearly twenty years of finance and
biotech accomplishments to BioCryst. We expect his experience and
reputation in the industry to enable us to sustain our solid financial
footing and to help us achieve our goal of building an enduring,
successful biopharmaceutical company."
Mr. Staab is a highly qualified pharmaceutical executive who over the
last decade has served as Chief Financial and Accounting Officer of two
growing NASDAQ-listed companies. He brings strong skills and experience
in the financial stewardship of publically-traded companies, development
and commercialization of pharmaceutical products and raising funds
through strategic partnerships, equity and debt financings.
Most recently, Mr. Staab served as Executive Vice President, CFO and
Treasurer of Inspire Pharmaceuticals from May 2003 through its $430
million acquisition by Merck & Co., Inc. in May 2011. Prior to joining
Inspire, he held senior financial positions of Acting CFO and Treasurer
at Triangle Pharmaceuticals, Inc., through its $465 million acquisition
by Gilead Sciences, Inc. in 2003. Before joining Triangle, Mr. Staab
spent eight years working for PricewaterhouseCoopers LLP providing audit
and business advisory services to national and multi-national
corporations in the biotechnology, pharmaceutical, pulp and paper and
communications industries. Tom currently serves on the Board of the
North Carolina Biosciences Organization and is a member of its Audit
Committee, and he has been received awards for his contribution and
leadership to other organizations. He is a Certified Public Accountant
and received a B.S. in Business Administration and a Masters of
Accounting from the University of North Carolina at Chapel Hill.
"I am excited about the opportunity to work with the entire BioCryst
team and to continue to build the company towards sustainability," said
Mr. Staab. "I feel privileged to be given the opportunity to join
BioCryst at such an exciting stage in its corporate development."
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel
small-molecule pharmaceuticals that block key enzymes involved in
infectious diseases, inflammatory diseases and cancer. BioCryst
currently has three novel late-stage compounds in development: peramivir,
a neuraminidase inhibitor for the treatment of influenza, BCX4208,
a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of
gout, and forodesine, an orally-available PNP inhibitor for
hematological malignancies. Utilizing crystallography and
structure-based drug design, BioCryst continues to discover additional
compounds and to progress others through pre-clinical and early
development to address the unmet medical needs of patients and
physicians. For more information, please visit the Company's website at www.biocryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC
and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
BioCryst Pharmaceuticals
Robert Bennett, 919-859-7910
Source: BioCryst Pharmaceuticals, Inc.
News Provided by Acquire Media